x
ServiziMenu principaleHome
You are here:  > Educational Opportunities > Future Events > Certificate of Advanced Studies in Prostate cancer - second cohort (CAS-Pr2)
Share on Share on Facebook Twitter Share on Linkedin Share on WhatsApp Share on Instagram Share by email Print this page

Certificate of Advanced Studies in Prostate cancer - second cohort (CAS-Pr2)

01.09.2025  -  30.09.2026

POSTGRADUATE PROGRAMME

Information

Applications will open soon.

Postgraduate programme focused on the improvement of both the clinical and scientific capability of oncologists and aiming to ensure better-quality management of patients with prostate cancer.

  • Duration: 13 months
  • Structure: 6 online modules & 3 in presence seminars: participation in PROSCA 2025, APCCC 2026 and ESO Learning to Care Seminar (LTC) 2026
  • Collaborating university: Università della Svizzera italiana (USI), Switzerland
  • Chairs: Andrea Gallina, CH; Silke Gillessen, CH; Barbara Jereczek-Fossa, IT; Ursula Vogl, CH

Upon successful completion of the programme and after passing the final exam, participants will obtain an academic certificate issued by the European School of Oncology and the Università della Svizzera italiana and a diploma supplement issued by the Università della Svizzera italiana.

ESO COLLEGE MEMBERSHIP

Being selected to take part in this course is one of the ESO activities that gives participants eligibility to enrol in ESO’s College. The course also enables members of the College to earn credits and therefore access more membership benefits. Full and active participation in the course as well as passing the final certificate examination earns participants 400 ESO College credits.

KEY DATES
  • Application opening: TBD
  • Application deadline: 30 April 2025
  • Notification of admission to applicant: 15 June 2025
  • Start date: September 2025 (exact date TBD)
  • Seminar 1: November 2025, PROSCA 2025 (exact dates and location TBD)
  • Seminar 2: 29 April-2 May 2026, APCCC Conference, Lugano, Switzerland
  • Seminar 3 and finale exam: September 2026 (exact date TBD), ESO Learning to Care Seminar (LTC) 2026, Padova, Italy

 For further information contact Sarah Ortelli: sortelli@eso.net

LINK TO THE PLATFORM HERE.

Curriculum

Entry Requirements

Admission

Admission to the Certificate of Advanced Studies in Prostate cancer (CAS-Pr) programme will be by competitive application only and the selection will be based on the eligibility criteria and on the selection procedure.

Applications will be considered if received completed with all required documents and within the deadline. Attendance is limited to 25 participants.

Decisions on admissions are made by the appointed Programme Chair.

Attendance

To obtain the Certificate of Advanced Studies in Prostate cancer, it will be compulsory that participants will attend all seminars and modules according to the provided timeline.

Insurance

The organisers bear no responsibility for untoward events in relation to the participation in the seminars. Participants are advised to take out their own personal and travel insurance coverage.

Eligibility

The CAS-Pr program is designed for medical doctors (medical oncology, radiation oncology, radiology, nuclear medicine or pathology), but it is equally accessible to graduates in natural sciences, who are engaged in the field of prostate cancer.

  1. Medical doctors:
    • Master degree from an accredited college or university (e.g. state examination in medicine) in medicine or an equivalent degree at the level of state examination in medicine and have had at least two years residency training in a relevant institution.
  2. Natural scientists:
    • Master degree from an accredited college or university in a course of studies in natural sciences or an equivalent degree at the level of at least three years of studies or in a course of studies with essentially the same contents at an accredited college or university and at least two years of professional experience in oncology.
  3. The following additional achievements will increase the assessment rate of the application:
    • Further professional experience related to the course of studies
    • Completion of an additional qualification in oncology (specialist training as a physician or international equivalent)
    • Publications, as evidenced by cumulative impact factors greater than 10
    • At least one year of relevant oncological experience in a foreign country

 

Application

ATTENDANCE TO THIS CERTIFICATE IS BY APPLICATION ONLY.

25 PARTICIPANTS WILL BE SELECTED.

Applications deadline: 30 April 2025

IDEAL PROFILE OF THE CERTIFICATE CANDIDATE:
  • Completed specialisation in oncology at least 2 years ago
  • Involvement in scientific activities and clinical trials
  • Fluency in English
  • From ESO’s geographical reach: Europe, Mediterranean countries and Latin America
  • Aged up to 50 years

Priority will also be given to candidates who:

  • Have previously participated in ESO’s activities
  • Are members of ESO’s College.
HOW TO APPLY

Interested candidates should apply online (at the top of this page).

The application process involves completing an online questionnaire, where you will provide details about:

  • Your work experience and training
  • Your research experience and publications
  • Your motivation and personal commitment to participating in this activity

During the application, you will also need to upload the following documents in PDF or JPEG format:

  • Recommendation letter: A letter from your head of department or mentor, written on official hospital letterhead and signed.
  • Curriculum Vitae (CV)
  • Copy of medical degree or equivalent degree in medicine or natural sciences or any other study programme covering the same contents in the original language and a certified English translation
  • Copy of transcript of records of the examinations taken during the medical degree programme in the original language and a certified English translation
  • If the point above is not applicable, please provide a record of all study achievements and examination results obtained in the course of studies until the application deadline
  • Employment verification/reference letters accounting for professional experience in oncology
  • Supporting documents to verify additional qualifications

You should also view this Data Protection statement and you will be asked to confirm that you ‘accept’ this statement during the application process.

SELECTION PROCESS

Applications are evaluated through a two-step process:

  1. Automated Scoring: Some responses are assessed using a predefined scoring system to ensure fairness and consistency. Points are assigned based on your answers.
  2. Committee Evaluation: Other sections, including your qualitative responses, are reviewed and scored by our selection committee.

This type of evaluation ensures a transparent and unbiased selection of top candidates for participation in this activity.

Tuition Fee

In keeping with the mission of the European School of Oncology, ESO generously subsidizes the cost of the CAS-Pr programme.  The tuition fee which remains to be paid by each participant is EUR 4’900.  A CAS Financial Aid Fund will be available for participants who cannot cover the full fee directly.

The tuition fee includes:

  • Access to the modules via a dedicated online platform
  • Access to the three in-person seminars foreseen by the programme, including registration for the indicated congresses and accommodation
  • Access to all exams required by the programme

The tuition fee does not include travel to the in-person seminars.

Cancellation

Cancellation should be submitted in writing and will be treated on a case-to-case basis.

Our Experts

Chairs
  • Andrea Gallina, Ente Ospedaliero Cantonale, CH
  • Silke Gillessen, Oncology Institute of Southern Switzerland, CH
  • Barbara Jereczek-Fossa, European Institute of Oncology, IT
  • Ursula Vogl, Oncology Institute of Southern Switzerland, CH
Scientific Directors
  • Andrea Alimonti, Institute of Oncology Research, CH
  • Elena Castro, Hospital Universitario Virgen de la Victoria, E
  • Eva Compérat, Medizinischen Universität Wien, A
  • Stefano Fanti, University of Bologna, I
  • Karim Fizazi, Institut Gustave Roussy, F
  • Andrea Gallina, Ente Ospedaliero Cantonale, CH
  • Rossella Graffeo, Oncology Institute of Southern Switzerland, CH
  • Silke Gillessen, Oncology Institute of Southern Switzerland, CH
  • Ken Herrmann, Universitäts­klinikum Essen, D
  • Barbara Jereczek-Fossa, European Institute of Oncology, Milan, I
  • Piet Ost, Cancer Research at Ghent University, B
  • Jean-Philippe Theurillat, Institute of Oncology Research, CH
  • Ursula Vogl, Oncology Institute of Southern Switzerland, CH
  • Thomas Zilli, University of Geneva, CH